13D Filings
LENZ Therapeutics, Inc.
LENZ
Amendment
Ownership

4.90%

Total Shares

1,400,220

Issuer CIK

1815776

CUSIP

52635N103

Event Date

Aug 17, 2025

Accepted

Aug 20, 2025, 05:13 PM

Reporting Persons (9)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Versant Venture Capital VI, L.P.
Partnership
4.90%1,400,2201,400,2200
Versant Ventures VI GP, L.P.
Partnership
4.90%1,400,22001,400,220
Versant Ventures VI GP-GP, LLC
Other
4.90%1,400,22001,400,220
Versant Ventures VII GP-GP, LLC
Other
3.60%1,033,41201,033,412
Versant Venture Capital VII, L.P.
Partnership
3.60%1,033,4121,033,4120
Versant Ventures VII GP, L.P.
Partnership
3.60%1,033,41201,033,412
Versant Vantage II, L.P.
Partnership
3.00%842,162842,1620
Versant Vantage II GP, L.P.
Partnership
3.00%842,1620842,162
Versant Vantage II GP-GP, LLC
Other
3.00%842,1620842,162
Disclosure Items (2)

Security Title

Common Stock, par value $0.00001 per share

Issuer Name

LENZ Therapeutics, Inc.

Issuer Address

201 Lomas Santa Fe Dr., Solana Beach, CA, 92075

Percentage of Class

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Number of Shares

See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments.

Transactions

On August 15, 2025, Versant VI sold 145,051 shares of Common Stock at a price per share of $39.500 for aggregate proceeds of approximately $5,729,514.50. On August 15, 2025, Versant VII sold 69,949 shares of Common Stock at a price per share of $39.500 for aggregate proceeds of approximately $2,762,985.50. On August 18, 2025, Versant VI sold 30,628 shares of Common Stock at a weighted average price per share of $38.5611 for aggregate proceeds of approximately $1,181,049.37. On August 18, 2025, Versant VII sold 15,085 shares of Common Stock at a weighted average price per share of $38.5611 for aggregate proceeds of approximately $581,694.19.

LENZ Therapeutics, Inc. — Schedule 13D | 13D Filings